Latest Expert Opinions

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
September 22, 2017

(A Top Pick Oct 27/16. Up 4%.) Sold this a while ago. Felt there was a lot more competition on the clothing side, and they were losing share there.

Nike Inc (NKE-N)
September 22, 2017

(A Top Pick Oct 27/16. Up 4%.) Sold this a while ago. Felt there was a lot more competition on the clothing side, and they were losing share there.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$53.240
Owned
No
WAIT
WAIT
September 22, 2017

Movies have had a difficult time of late. They’ve had a very bad summer season for blockbusters. People are not as eager to go to movie theatres unless there is something really, really important they want to see. The company has done a very good job with concessions. He would wait for another quarter or so before looking at this.

Cineplex Inc (CGX-T)
September 22, 2017

Movies have had a difficult time of late. They’ve had a very bad summer season for blockbusters. People are not as eager to go to movie theatres unless there is something really, really important they want to see. The company has done a very good job with concessions. He would wait for another quarter or so before looking at this.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$39.550
Owned
Unknown
HOLD
HOLD
September 22, 2017

He likes this. It is not expensive and pays a decent dividend. A couple of things have happened that has hurt. Other companies cut back on fixed income, currency and commodity (FCC) side of the business because it is a very highly intensive capital business from a regulatory point of view. Goldman decided not to do that as much. They are still #1 in cash equities, etc.

Goldman Sachs (GS-N)
September 22, 2017

He likes this. It is not expensive and pays a decent dividend. A couple of things have happened that has hurt. Other companies cut back on fixed income, currency and commodity (FCC) side of the business because it is a very highly intensive capital business from a regulatory point of view. Goldman decided not to do that as much. They are still #1 in cash equities, etc.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$231.030
Owned
No
COMMENT
COMMENT
September 22, 2017

People think of this as a credit card, but it really is a toll road. They get paid every time someone uses a visa card. There have been very few pullbacks where you can buy the stock. The one slight risk to these companies is that a lot of times the payment side is being disintermediated globally with new FinTech technology. Nevertheless, this has been a great story.

Visa Inc. (V-N)
September 22, 2017

People think of this as a credit card, but it really is a toll road. They get paid every time someone uses a visa card. There have been very few pullbacks where you can buy the stock. The one slight risk to these companies is that a lot of times the payment side is being disintermediated globally with new FinTech technology. Nevertheless, this has been a great story.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$105.560
Owned
Unknown
BUY
BUY
September 22, 2017

One of the premier oil companies in Canada. They are very astute at making acquisitions and integrating them, and have made a bunch in the last little while. Also, every time they have worked on a project through the years, they have always been on time. At this level, this should be okay.

One of the premier oil companies in Canada. They are very astute at making acquisitions and integrating them, and have made a bunch in the last little while. Also, every time they have worked on a project through the years, they have always been on time. At this level, this should be okay.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$42.090
Owned
Yes
COMMENT
COMMENT
September 22, 2017

The trouble with these kind of drug companies is that they made lots of acquisitions, which is how they have grown. Many were considered growth companies because they came out with social drugs, and ended up with huge multiples. There are lots of good things in their pipeline, but there are not going to be these massive, massive blockbuster drugs they used to have.

Pfizer Inc (PFE-N)
September 22, 2017

The trouble with these kind of drug companies is that they made lots of acquisitions, which is how they have grown. Many were considered growth companies because they came out with social drugs, and ended up with huge multiples. There are lots of good things in their pipeline, but there are not going to be these massive, massive blockbuster drugs they used to have.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$35.960
Owned
No
COMMENT
COMMENT
September 22, 2017

Not the kind of stock he would buy, because the valuation doesn’t work for. They have 52 million US subscribers and 52 million international subscribers. They have a great brand and are way ahead of everybody else, and are developing their own products. He can see them having great pricing power over the next little while because of their strong brand. Thinks there is still a lot of growth to the story.

Netflix Inc. (NFLX-Q)
September 22, 2017

Not the kind of stock he would buy, because the valuation doesn’t work for. They have 52 million US subscribers and 52 million international subscribers. They have a great brand and are way ahead of everybody else, and are developing their own products. He can see them having great pricing power over the next little while because of their strong brand. Thinks there is still a lot of growth to the story.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$187.350
Owned
No